Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
WALTHAM, Mass., Nov. 01, 2016 -- BeiGene, Ltd. (Nasdaq:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced that John V. Oyler, Founder, Chief Executive Officer, and Chairman, and Howard Liang, Ph.D., Chief Financial Officer and Chief Strategy Officer, will present at the 25th Annual Credit Suisse Healthcare Conference in Scottsdale, Arizona. The presentation is scheduled for 3:00PM MST on November 7, 2016.
A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.
Media/Investor Contact: Lucy Li, Ph.D. +1 781-801-1800 [email protected] [email protected]
